

Bard1 Life Sciences Ltd

10:30 03 Jul 2017

BARD1 Life Sciences Ltd targets cash injection

BARD1 Life Sciences Ltd (ASX:BD1) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The company is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

The halt will remain in place until the opening of trade on Wednesday 5th July 2017, or earlier if an announcement is made to the market.

Price: A\$0.035

Market Cap: A\$47.85M

1 Year Share Price Graph



Share Information

Code: BD1

Listing: ASX

52 week High Low
A\$0.07 A\$0.01

Sector: Pharma & Biotech

Website: www.bard1.com

Company Synopsis:

Bard1 Life Sciences Ltd (ASX:BD1) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.